A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Key facts
- Where
- San Juan, Puerto RicoSee the site
- Phase
- Phase 3
Where in Puerto Rico
- Latin Clinical Trial CenterSan Juan, Puerto RicoNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881458EU 2026-527230-31-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.
Inclusion: Have type 2 diabetes; Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥27 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following within 90 days prior to screening; medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies; dipeptidyl peptidase 4 (DPP-4) inhibitors, and; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.